Table 2.
Univariate Analysis of clinical characteristics and blood index on PFS and OS
| Characteristic | PFS | OS | ||||
|---|---|---|---|---|---|---|
| P-value | HR | 95% CI | P-value | HR | 95% CI | |
| Clinic index | ||||||
| Sex (male/female) | 0.081 | 1.647 | 0.941-2.883 | 0.737 | 1.124 | 0.567-2.229 |
| Age (<65 / ≥ 65 yr) | 0.320 | 1.425 | 0.708-2.867 | 0.001 | 3.878 | 1.686-8.921 |
| Metastasis (< 3 / ≥ 3) | 0.039 | 2.146 | 1.038-4.436 | 0.012 | 2.826 | 1.256-6.361 |
| Smoke (never / ever) | 0.399 | 0.786 | 0.449-1.376 | 0.852 | 0.937 | 0.472-1.858 |
| Histology (SC / AD) | 0.794 | 1.086 | 0.585-2.017 | 0.350 | 1.489 | 0.646-3.435 |
| Clinical Stage (IIIB / IV) | 0.805 | 1.123 | 0.446-2.832 | 0.839 | 1.115 | 0.389-3.198 |
| PS (0-1/ ≥ 2) | 0.636 | 0.883 | 0.528-1.477 | 0.419 | 1.320 | 0.673-2.590 |
| Therapy strategy★ | 0.645 | 0.786 | 0.282-2.189 | 0.370 | 0.516 | 0.122-2.189 |
| Line of therapy (1/2/3/5) | 0.128 | 1.319 | 0.923-1.884 | 0.016 | 1.699 | 1.105-2.613 |
| Type of immunotherapy※ | 0.582 | 0.886 | 0.575-1.364 | 0.611 | 1.098 | 0.767-1.571 |
| irAE (class I) * | 0.060 | 0.573 | 0.321-1.023 | 0.085 | 0.512 | 0.239-1.098 |
| irAE (class II) ** | 0.016 | 0.395 | 0.185-0.843 | 0.025 | 0.196 | 0.047-0.818 |
| Response # | <0.001 | 9.203 | 4.738-17.877 | 0.009 | 1.978 | 1.181-3.310 |
| Blood index | ||||||
| NLR C1 (< 5 / ≥ 5) | 0.431 | 0.709 | 0.301-1.670 | 0.520 | 0.676 | 0.205-2.226 |
| NLR C4 (< 5 / ≥ 5) | 0.002 | 3.060 | 1.521-6.150 | 0.194 | 1.741 | 0.754-4.022 |
| PLT (≤ 350 / > 350×109/L) | 0.532 | 0.794 | 0.386-1.635 | 0.755 | 0.868 | 0.357-2.110 |
| LDH (≤ 369 / > 369 U/L) | 0.965 | 0.977 | 0.349-2.734 | 0.163 | 2.118 | 0.737-6.087 |
| CEA (≤ 5 / > 5 ng/ml) | 0.014 | 0.437 | 0.225-0.846 | 0.086 | 0.513 | 0.240-1.099 |
HR: Hazard ratio; SC: Squamous cell carcinoma; AD: Adenocarcinoma; Therapy strategy★: mono-immunotherapy or doublet-immunotherapy; Type of immunotherapy※: anti-PD-1/anti-PD-L1/anti-PD-1+anti-CTLA4; *: no irAE/any irAE; **: irAE<G2 /irAE≥ G2; Response #: PR/SD/PD; NLR: neutrophil lymphocyte rate; PLT: Platelet; LDH: Lactate dehydrogenase; CEA: Carcinoembryonic antigen.